A NEW “game-changing” drug could stop the progression of Alzheimer’s disease, early trials suggest. Scientists say the ...

Trontinemab is a formulation of Roche's failed gantenerumab but now paired with the company's Brainshuttle technology to ...

Trontinemab is one of a class of new medicines aimed at clearing amyloid plaques. The new findings from phase two trials ...

TORONTO -- An investigational antibody drug, designed to cross the blood-brain barrier (BBB) to eliminate amyloid-beta ...

Swiss pharma major Roche (ROG: SIX) has outlined ambitious plans to accelerate the development of trontinemab, its ...

Roche’s Alzheimer’s disease therapy has continued to show benefit for patients after 28 weeks in a long-term extension study.

Swiss drugmaker Roche Holding plans to investigate whether an experimental medicine can delay or prevent Alzheimer’s disease ...

In a Phase Ib/IIa trial, 91% of patients receiving the highest dose of trontinemab were amyloid negative after seven months ...

There are currently estimated to be 982,000 people with some form of dementia, including Alzheimer's in the UK ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer’s ...

A new Alzheimer’s drug has been hailed as a major breakthrough after clinical trials showed it could clear the harmful brain ...

Genentech, a member of Roche (RHHBY), announced that new data from its Alzheimer’s development portfolio is being presented at the Alzheimer’s ...